Allschwil, Switzerland-based Idorsia Ltd recently announced its financial results for the first half of 2021, at which time its drug daridorexant for the treatment of insomnia under review with United States FDA, EMA, and Swissmedic.

Simon Jose, chief commercial officer of Idorsia, says in a release, “We are progressing very well with our preparations for the anticipated approval and launch of daridorexant. In the US, our new medical team is starting to engage with key experts and the recruitment of our market access team is nearing completion. In Europe, we have made great progress in building our commercial footprint and have appointed General Managers in the major markets. In the second half we will increase our engagement with key stakeholders and begin to raise awareness of the science and burden of insomnia.”